LBX(SH:603883)2018-10-24 16:00Financial Performance - Operating revenue for the first nine months reached CNY 6,771,969,891, a year-on-year increase of 28.77%[6] - Net profit attributable to shareholders was CNY 324,663,064, reflecting an 18.33% increase year-on-year[6] - Basic earnings per share rose by 10.68% to CNY 1.14[6] - Total revenue for Q3 2018 reached ¥2,334,723,994, a 29.4% increase from ¥1,804,376,172 in Q3 2017[28] - Net profit for Q3 2018 was ¥118,454,274, representing a 32.5% increase compared to ¥89,419,294 in Q3 2017[29] - Year-to-date revenue for 2018 is CNY 1,522,742,918, up 24.9% from CNY 1,217,674,354 in the same period last year[33] - Year-to-date net profit for 2018 is CNY 70,796,368, down 84.2% from CNY 448,893,830 in the same period last year[34] Assets and Liabilities - Total assets increased by 14.94% to CNY 7,699,605,458 compared to the end of the previous year[6] - The total current assets as of September 30, 2018, amounted to 4,156,079,542 RMB, an increase from 3,979,435,674 RMB at the beginning of the year[20] - The company's total liabilities reached 4,499,929,767 RMB, compared to 3,597,779,484 RMB at the beginning of the year[22] - The total assets as of Q3 2018 amounted to ¥5,188,006,576, an increase from ¥4,809,920,138 in the previous year[26] - Current liabilities totaled ¥1,696,761,029, up from ¥1,105,813,107 in the same period last year[26] - The total liabilities as of Q3 2018 were ¥2,491,620,594, compared to ¥1,899,385,259 in the previous year[26] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 587,355,657, up 11.68% from the previous year[6] - Cash flow from operating activities for the first nine months of 2018 was CNY 6,699,258,803, an increase from CNY 6,454,078,784 in the same period last year[36] - Operating cash inflow for Q3 2018 was CNY 6,739,964,177, an increase of 3.8% from CNY 6,491,720,447 in Q3 2017[37] - Cash outflow from investing activities totaled CNY 764,454,586 in Q3 2018, compared to CNY 233,754,884 in Q3 2017, indicating a substantial increase in investment spending[40] - Net cash flow from financing activities for Q3 2018 was CNY 79,795,918, recovering from a negative CNY 19,458,989 in Q3 2017[40] Shareholder Information - The total number of shareholders reached 10,608 by the end of the reporting period[8] - The largest shareholder, Hunan Laobaixing Pharmaceutical Investment Management Co., held 34.81% of shares[8] - The company's equity attributable to shareholders increased slightly from 2,930,827,300 RMB to 2,936,103,978 RMB[22] Investments and Acquisitions - Long-term equity investments increased by 100% to CNY 15,150,000 due to new equity investments made during the period[10] - The company’s short-term borrowings rose by 270.26% to CNY 645,000,000, primarily due to new borrowings in the current period[10] - The company acquired land use rights in Changsha for 37.835 million RMB, covering an area of 9,670.67㎡[16] - Three new acquisition projects were implemented during the reporting period, with total costs of 2.2 million RMB, 2.5 million RMB, and 3.2 million RMB respectively[17] - The company completed the acquisition of 16 stores from Guangxi Canzhilin Pharmaceutical Co., Ltd. for 2.2 million RMB by September 30, 2018[17] Operational Metrics - The number of direct stores reached 3,110, with 676 new stores added during the reporting period, including 421 direct stores and 303 acquired stores[13] - The gross margin for the pharmaceutical retail segment was 38.62%, with a year-on-year increase of 0.25%[12] - The operating revenue from the North China region surged by 178.57% to CNY 782,407,570, indicating strong regional performance[12] Research and Development - Research and development expenses for Q3 2018 were ¥3,086,365, with a total of ¥5,775,767 for the year-to-date[29] - Research and development expenses for the first nine months of 2018 totaled CNY 3,953,626[33]